Latest News

Noxopharm (ASX:NOX) has announced that the latest formal review by the NOXCOVID-1 Safety Steering Committee has cleared it to advance to the fifth and final dosage cohort.

Completing the ‘Update online roadshow’ AusBiotech members from Queensland and Western Australian are invited to hear the latest information from their State Government representative at AusBiotech’s Industry Update, which aims to grow and support the biotech industry.

A QIMR Berghofer-led randomised controlled trial of vitamin D supplements has found they do not protect most people from developing colds, cases of flu and other acute respiratory infections.

Telix Pharmaceuticals (ASX:TLX) and partner ARTMS have announced they have successfully produced Telix's prostate cancer imaging product, TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11).

Australian seed-to-patient medicinal cannabis producer Cannatrek has announced it will supply medicinal cannabis products to LYPHE Group in support of Project TWENTY21, Europe’s first and largest national medical cannabis registry.

Pharmaxis (ASX:PXS) has received a US$7 million milestone payment from its US licensee Chiesi following the recent FDA approval of BRONCHITOL (mannitol) for the treatment of cystic fibrosis.

Health minister Greg Hunt has announced $20 million in funding for two new medical research centres that will focus on producing rapid improvements in the prevention and treatment of diabetes and cardiovascular disease.

As the country returns after the festive break and the realities of ‘COVID-normal’ and the respective New Year’s resolutions settle on us, AusBiotech starts the year focused on leadership in policy, and a resolution to continue committed advocacy for innovation in life sciences.

Boehringer Ingelheim has become the first pharmaceutical company to partner with Google in quantum computing with a three-year agreement and a newly established Quantum Lab of Boehringer Ingelheim.

US-based BIO has secured a preliminary injunction blocking the adoption of the 'most favoured nation' pricing policy for a key US government prescription medicine program.

Ena Respiratory says published research on its novel nasal spray therapy, INNA-051, shows it has reduced COVID-19 viral replication by up to 96 per cent in a gold standard ferret study.

The Brandon Capital managed Medical Research Commercialisation Fund (MRCF) has announced the appointment of Erica Kneipp to its board.